tiprankstipranks
Advertisement
Advertisement
Orasis Pharmaceuticals Highlights Early Qlosi Performance One Year After Launch
PremiumPrivate CompaniesOrasis Pharmaceuticals Highlights Early Qlosi Performance One Year After Launch
18d ago
Orasis Pharmaceuticals Steps Up Presbyopia, Pilocarpine Education Push at SECO 2026
Premium
Private Companies
Orasis Pharmaceuticals Steps Up Presbyopia, Pilocarpine Education Push at SECO 2026
2M ago
Orasis Highlights Presbyopia Education and Pilocarpine Data Engagement at SECO Meeting
Premium
Private Companies
Orasis Highlights Presbyopia Education and Pilocarpine Data Engagement at SECO Meeting
2M ago
Orasis Highlights Clinician Education Effort on Presbyopia Eye Drops
PremiumPrivate CompaniesOrasis Highlights Clinician Education Effort on Presbyopia Eye Drops
2M ago
Orasis Pharmaceuticals Highlights Scientific Engagement at SECO 2026
Premium
Private Companies
Orasis Pharmaceuticals Highlights Scientific Engagement at SECO 2026
2M ago
Orasis Pharmaceuticals Targets Clinical Visibility With SECO 2026 Pilocarpine Focus
Premium
Private Companies
Orasis Pharmaceuticals Targets Clinical Visibility With SECO 2026 Pilocarpine Focus
2M ago
Patient Experience Story Points to Ongoing Commercial Push at Orasis Pharmaceuticals
PremiumPrivate CompaniesPatient Experience Story Points to Ongoing Commercial Push at Orasis Pharmaceuticals
3M ago
Orasis Pharmaceuticals – Weekly Recap
Premium
Private Companies
Orasis Pharmaceuticals – Weekly Recap
3M ago
Orasis Pharmaceuticals Highlights New Pilocarpine Data Supporting Low-Concentration Presbyopia Strategy
Premium
Private Companies
Orasis Pharmaceuticals Highlights New Pilocarpine Data Supporting Low-Concentration Presbyopia Strategy
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100